drugset / Trial / NCT07007910
Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK（pharmacokinetics） and PD（pharmacodynamics） of HSK46575 when given orally in patients with metastatic castration-resistant prostate cancer.
Timeline
- Start
- 2024-12-18
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK46575 | Unknown | — | Oral |